Phase III Trial of Doxorubicin, Paclitaxel, and the Combination of Doxorubicin and Paclitaxel as Front-Line Chemotherapy for Metastatic Breast Cancer: An Intergroup Trial (E1193)
Top Cited Papers
- 15 February 2003
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (4), 588-592
- https://doi.org/10.1200/jco.2003.08.013
Abstract
Purpose: Between February 1993 and September 1995, 739 patients with metastatic breast cancer were entered on an Intergroup trial (E1193) comparing doxorubicin (60 mg/m2), paclitaxel (175 mg/m2/24 h), and the combination of doxorubicin and paclitaxel (AT, 50 mg/m2 and 150 mg/m2/24 h, plus granulocyte colony-stimulating factor 5 mg/kg) as first-line therapy. Patients receiving single-agent doxorubicin or paclitaxel were crossed over to the other agent at time of progression. Patients and Methods: Patients were well balanced for on-study characteristics. Results: Responses (complete response and partial response) were seen in 36% of doxorubicin, 34% of paclitaxel, and 47% of AT patients (P = .84 for doxorubicin v paclitaxel, P = .007 for v AT, P = .004 for paclitaxel v AT). Median time to treatment failure (TTF) is 5.8, 6.0, and 8.0 months for doxorubicin, paclitaxel, and AT, respectively (P = .68 for doxorubicin v paclitaxel, P = .003 for doxorubicin v AT, P = .009 for paclitaxel v AT). Median survivals are 18.9 months for patients taking doxorubicin, 22.2 months for patients taking paclitaxel, and 22.0 months for patients taking AT (P = not significant). Responses were seen in 20% of patients crossing from doxorubicin → paclitaxel and 22% of patients crossing from paclitaxel → doxorubicin (P = not significant). Changes in global quality-of-life measurements from on-study to week 16 were similar in all three groups. Conclusion: (1) doxorubicin and paclitaxel, in the doses used here, have equivalent activity; (2) the combination of AT results in superior overall response rates and time to TTF; and (3) despite these results, combination therapy with AT did not improve either survival or quality of life compared to sequential single-agent therapy.Keywords
This publication has 14 references indexed in Scilit:
- Paclitaxel (Taxol)New England Journal of Medicine, 1995
- Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer.Journal of Clinical Oncology, 1993
- Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast CancerJNCI Journal of the National Cancer Institute, 1991
- VP-16 + adriamycin vs. Adriamycin alone in advanced adenocarcinoma of the breast, phase II, a randomized trial: A southwest oncology group studyMedical and Pediatric Oncology, 1988
- The effect on survival of initial chemotherapy in advanced breast cancer: polychemotherapy versus single drug.Journal of Clinical Oncology, 1987
- Weekly Adriamycin versus VAC in advanced breast cancer. A randomized trialEuropean Journal of Cancer and Clinical Oncology, 1986
- Adriamycin alone or combined with vincristine in the treatment of advanced breast cancerEuropean Journal of Cancer and Clinical Oncology, 1983
- Single-drug vs combination cytotoxic chemotherapy in advanced breast cancer: A randomized studyEuropean Journal of Cancer (1965), 1980
- Combination chemotherapy for metastatic breast carcinoma.Prospective comparison of multiple drug therapy with L-phenylalanine mustardCancer, 1976
- Chemotherapy of advanced breast cancer: a controlled randomized trial of cyclophosphamide versus a four-drug combinationBritish Journal of Cancer, 1975